Use of SRPK3 gene in preparing medicine for treating myocardial hypertrophy

By knocking out or inhibiting the SRPK3 gene, the development of inhibitors targeting SRPK3 has solved the problem of cardiac hypertrophy treatment, significantly alleviating cardiac cell hypertrophy and fibrosis, improving cardiac contraction function, and providing a new method to treat cardiac hypertrophy.

CN116898971BActive Publication Date: 2024-11-22RENMIN HOSPITAL OF WUHAN UNIVERSITY (HUBEI GENERAL HOSPITAL)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310873792.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-07-17
Publication Date
2024-11-22
Estimated Expiration
2043-07-17

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat myocardial hypertrophy, resulting in decompensation of the heart structure and function, increasing the risk of cardiovascular disease, and SRPK3 has been studied in heart disease less.

Method used

By knocking out or inhibiting the SRPK3 gene, using it as a drug target, SRPK3 gene expression inhibitors are developed to prevent, alleviate and treat myocardial hypertrophy, including inhibitors such as nucleic acids, adenoviruses and small molecule compounds, combining interfering plasmids and adenoviruses Transfection technology, entering cells to achieve targeted therapy.

Benefits of technology

It significantly reduces cardiomyocyte hypertrophy and fibrosis and improves cardiac contraction function, provides a new method to treat cardiac hypertrophy and enriches the drug library for cardiac hypertrophy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116898971B_ABST
    Figure CN116898971B_ABST
Patent Text Reader

Abstract

The present invention discloses the use of the SRPK3 gene in the preparation of a drug for treating myocardial hypertrophy. The sequence of the SRPK3 gene is shown in SEQ ID NO.1. The SRPK3 gene expression inhibitor is a substance prepared or screened with the SRPK3 gene as a target and has an inhibitory effect on the SRPK3 gene. The present invention found that compared with the normal group, the expression of SRPK3 in the myocardial hypertrophy model mice was significantly upregulated, the heart weight / body weight, lung weight / body weight, myocardial cell cross-sectional area and fibrosis of the SRPK3 gene knockout mice were significantly reduced, and the cardiac contractile function was significantly improved. Based on the above findings, SRPK3 can be used as a target for drugs for treating myocardial hypertrophy and heart failure, and its inhibitor can be used to prepare drugs for preventing, alleviating and / or treating pathological myocardial hypertrophy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine, and particularly relates to the use of SRPK3 gene in preparing a medicine for treating myocardial hypertrophy. Background Art

[0002] Myocardial hypertrophy is a pathological change caused by long-term pressure or volume overload of the heart. It is common in patients with cardiovascular diseases such as hypertension and heart valve disease. It is mainly manifested by the increase in heart volume and weight caused by myocardial cell hypertrophy and increased sarcomeres. Early myocardial hypertrophy is characterized by myocardial cell hypertrophy and increased myocardial contractility. As a compensatory mechanism to maintain cardiac output and peripheral circulation perfusion, long-term heart enlargement increases myocardial oxygen consumption and reduces ventricular wall compliance, leading to decompensation of cardiac structure and function. Before early myocardial hypertrophy, the mitochondrial ultrastructure and metabolism of myocardial cells have changed. At the same time, the phenotype of myocardial cells undergoes embryonic transformation, accompanied by myocardial interstitial cell proliferation and cardiac extracellular matrix deposition, leading to myocardial remodeling and heart failure. Long-term myocardial hypertrophy is prone to induce cardiovascular diseases such as malignant arrhythmias, coronary heart disease, heart valve stenosis or insufficiency, and is closely related to other cardiovascular diseases such as cardiometabolic diseases and sudden cardiac death.

[0003] Serine-arginine protein kinases (SRPKs) are a class of cell cycle-dependent kinases that participate in the splicing regulation of precursor messenger RNA (pre-mRNA) mainly by phosphorylating proteins rich in serine-arginine sequences, and control the subcellular localization of splicing regulatory factors; in addition, SRPKs participate in the regulation of cell cycle and apoptosis. Due to these functions, SRPKs may play a role in tumorigenesis. In addition to splicing regulatory factors, SRPKs are also involved in the phosphorylation of a variety of proteins. For example, SRPK2 phosphorylates Tau protein to cause the occurrence and development of Alzheimer's disease, and SRPKs phosphorylate viral proteins (such as HBV core protein) and regulate their replication process. SRPKs are a family of kinases that control alternative splicing and are associated with many types of cancer. Targeting SRPKs has proposed a potential strategy to inhibit cancer cell proliferation and metastasis by regulating abnormal alternative splicing. Among them, SRPK3 is a class of muscle-specific protein kinases that participates in the occurrence and development of diseases such as Parkinson's disease, but SRPK3 has not yet been reported in heart disease. Summary of the invention

[0004] Applicants found Srpk fl / f After SRPK3 gene knockout in mice, Srpk fl / flCompared with mice, heart weight / body weight, lung weight / body weight, myocardial cell cross-sectional area and fibrosis were significantly reduced, and cardiac contractile function was significantly improved. These results indicate that SRPK3 gene knockout alleviates the disease progression of pathological myocardial hypertrophy. Based on the above findings, the SRPK3 gene can be used as a drug target for screening the treatment of myocardial hypertrophy and heart failure, and its inhibitors can be used to prepare drugs to prevent, alleviate and / or treat pathological myocardial hypertrophy.

[0005] The technical solution provided by the present invention is as follows:

[0006] In a first aspect, the present invention provides a use of an SRPK3 gene expression inhibitor in the preparation of a drug for preventing, alleviating and / or treating myocardial hypertrophy. The sequence of the SRPK3 gene is shown in SEQ ID NO.1. The SRPK3 gene expression inhibitor is a substance prepared or screened with the SRPK3 gene as the target and has an inhibitory effect on the SRPK3 gene.

[0007] On the basis of the above technical solution, the SRPK3 gene expression inhibitor is a nucleic acid, a nucleic acid construct, an adenovirus, a protein or a small molecule compound.

[0008] On the basis of the above technical solution, the SRPK3 gene expression inhibitor includes an interference plasmid, and the interference plasmid includes the sequence shown in SEQ ID NO.6.

[0009] Based on the above technical solution, the interference plasmid is packaged into adenovirus and enters the cell through adenovirus transfection.

[0010] On the basis of the above technical solution, the adenovirus is obtained by the following method: the interference plasmid containing the sequence shown in SEQ ID NO.6 and the adenovirus backbone vector pADEasy-1 are co-transfected into HEK293 cells to obtain the recombinant adenovirus.

[0011] On the basis of the above technical solution, myocardial hypertrophy is pathological myocardial hypertrophy, including myocardial hypertrophy or heart failure caused by one or more of hypertension, aortic stenosis, and mitral regurgitation.

[0012] In a second aspect, the present invention provides a drug for preventing, alleviating and / or treating myocardial hypertrophy, comprising one or more of the above-mentioned SRPK3 gene expression inhibitors.

[0013] In a third aspect, the present invention provides a combined drug combination for treating myocardial hypertrophy, wherein the drug combination comprises one or more of the above-mentioned SRPK3 gene expression inhibitors and at least one other drug for treating myocardial hypertrophy.

[0014] On the basis of the above technical solution, the combination of drugs for treating myocardial hypertrophy is selected from any one of the following forms:

[0015] (i) preparing the SRPK3 gene expression inhibitor and other drugs for treating myocardial hypertrophy into independent preparations;

[0016] (ii) The SRPK3 gene expression inhibitor and other drugs for treating myocardial hypertrophy are formulated into a compound preparation.

[0017] In a fourth aspect, the present invention provides a myocardial hypertrophy detection system, comprising:

[0018] A detection reagent or a combination of detection reagents that specifically recognizes SRPK3 protein; and

[0019] An instrument capable of quantitatively detecting a test reagent or combination of test reagents.

[0020] When the myocardial hypertrophy detection system detects that the content of SRPK3 protein in myocardial cells is higher than the normal value, it is judged as myocardial hypertrophy.

[0021] Compared with the prior art, the present invention has the following advantages and effects:

[0022] (1) The present invention found that inhibiting the SRPK3 gene can improve myocardial hypertrophy, providing a new idea for preventing, alleviating and / or treating myocardial hypertrophy by using the SRPK3 gene as an inhibition target.

[0023] (2) The present invention provides a variety of SRPK3 gene inhibitors and their use in preparing drugs for preventing, alleviating and / or treating myocardial hypertrophy, enriching the myocardial hypertrophy drug library. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 The protein expression of BNP, β-MHC and SRPK3 in the hearts of normal people and patients with clinical myocardial hypertrophy (heart failure patients) and their statistical bar graphs. β-Tubulin was used as an internal reference. The expression of SRPK3 was upregulated in the heart tissue of patients with myocardial hypertrophy (*: p < 0.05 vs the normal group).

[0025] Figure 2 The expression and statistical graph of BNP, β-MHC and SRPK3 in the heart of C57BL / 6 mice 2 weeks and 4 weeks after sham surgery and aortic arch constriction (TAC) modeling. β-Tubulin was used as an internal reference. The expression of SRPK3 was upregulated in the heart with myocardial hypertrophy (*: p < 0.05 vs sham surgery group).

[0026] Figure 3 This is the protein expression and statistical graph of SRPK3 in the control group and after angiotensin II stimulation in primary cardiomyocytes of neonatal rats cultured in vitro. β-Tubulin was used as an internal reference. SRPK3 expression was upregulated after angiotensin II stimulation (*: p<0.05vs control group).

[0027] Figure 4 It is the structure map of Ad-shSRPK3 plasmid and the verification and statistical chart of SRPK3 protein expression after SRPK3 gene knockdown. β-Tubulin was used as an internal reference, and it was found that SRPK3 expression was significantly reduced (*: p<0.05vsAd-shRNA group).

[0028] Figure 5 The immunofluorescence and cell surface area statistics of primary cardiomyocytes of neonatal rats cultured in vitro were infected with adenovirus Ad-shRNA and Ad-shSRPK3, and stimulated with angiotensin II for 48 hours. The adenovirus interfering with SRPK3 inhibited cardiomyocyte hypertrophy (*: p < 0.05 vs Ad-shRNA control group, #: p < 0.05 vs Ad-shRNA angiotensin II group).

[0029] Figure 6 It is SRPK3 fl / fl / Myh6-Cre and littermate wild-type SRPK3 fl / fl Statistical graphs of heart size, heart weight / body weight, lung weight / body weight, and heart weight / tibia length in mice 4 weeks after sham or TAC surgery (*: p < 0.05 vs SRPK3 fl / fl Sham operation group, #: p<0.05 vs SRPK3 fl / fl model group).

[0030] Figure 7 It is SRPK3 fl / fl / Myh6-Cre mice and wild-type littermates of SRPK3 fl / fl WGA staining of heart tissue and statistics of cardiomyocyte cross-sectional area 4 weeks after sham or TAC surgery in mice (*: p < 0.05 vs SRPK3 fl / fl Sham operation group, #: p<0.05 vs SRPK3 fl / fl model group).

[0031] Figure 8 It is SRPK3 fl / fl / Myh6-Cre and littermate wild-type SRPK3 fl / fl Masson trichrome staining of heart tissue and left ventricular collagen content in mice 4 weeks after sham surgery or TAC surgery (*: p < 0.05 vs SRPK3 fl / fl Sham operation group, #: p<0.05 vs SRPK3 fl / fl model group).

[0032] Fig. 9 It is SRPK3 fl / fl / Myh6-Cre and littermate wild-type SRPK3fl / fl Statistical graphs of M-mode echocardiography and cardiac function test results, including ejection fraction, left ventricular end-systolic diameter, left ventricular end-diastolic diameter and fractional shortening (*: p < 0.05 vs SRPK3) 4 weeks after sham or TAC surgery in mice fl / fl Sham operation group, #: p<0.05 vs SRPK3 fl / fl model group). DETAILED DESCRIPTION

[0033] The present invention is further described in detail below in conjunction with embodiments and drawings, but the embodiments of the present invention are not limited thereto.

[0034] The present invention uses myocardial cell-specific SRPK3 gene knockout mice (SRPK3 fl / fl / Myh6-Cre) and littermates with wild-type SRPK3 fl / fl Mice were used as experimental subjects. Transverse aortic constriction (TAC) was used to induce myocardial hypertrophy in order to study the function of the SRPK3 gene. The results showed that the expression of SRPK3 in the myocardial hypertrophy model was significantly upregulated compared with the normal group. fl / fl Compared with the model group mice, SRPK3 fl / fl The heart weight / body weight, lung weight / body weight, myocardial cell cross-sectional area and fibrosis of mice in the Myh6-Cre model group were significantly reduced, and the cardiac contractile function was significantly improved. These results indicate that myocardial cell-specific SRPK3 gene knockout can alleviate the disease progression of pathological myocardial hypertrophy. Therefore, the SRPK3 gene can be used as a drug target to construct an in vitro cell model or animal model of SRPK3 gene knockout, which can be used to screen drugs and / or biological agents for preventing, alleviating and / or treating myocardial hypertrophy, and achieve the purpose of preventing, alleviating and / or treating pathological myocardial hypertrophy through genetic engineering technology. In addition, small molecule compound inhibitors can be designed with SRPK3 as the target, and molecules that can specifically inhibit SRPK3 can be found through screening using in vitro cell models or animal models with overexpression of the SRPK3 gene, thereby providing new therapeutic molecules for the treatment of myocardial hypertrophy.

[0035] Experimental animals and feeding:

[0036] Experimental animals: 8-10 weeks old, weighing 25.5±2.0g, SRPK3 fl / fl / Myh6-Cre and littermate wild-type SRPK3 fl / fl Male mice were used as experimental subjects.

[0037] Housing environment: All experimental mice were housed in the Specific Pathogen Free (SPF) experimental animal center of the Institute of Cardiovascular Diseases, Wuhan University.

[0038] Rearing conditions: room temperature between 22-24℃, humidity between 50-70%, alternating light and dark lighting time of 12 hours, free access to water and food.

[0039] Example 1: Cardiomyocyte-specific SRPK3 gene knockout (SRPK3 fl / fl Construction of Myh6 / Myh6-Cre mice

[0040] 8-10 week old SRPK3 fl / fl Mice (purchased from Saiye (Suzhou) Biotechnology Co., Ltd.) were mated with Myh6-Cre mice (purchased from Jackson Laboratory, USA). After mating, the tails of the mice were cut and the gene was identified by enzymatic hydrolysis. SRPK3 was screened. fl / fl / Myh6-Cre mice, the primers used for enzymatic digestion are as follows:

[0041] F1 (SEQ ID NO.2):5'-AAAGGCTACTTTTGAGGCCTACTT-3';

[0042] R1 (SEQ ID NO.3):5'-AGGAGCACTTAGACTCCAGAAATG-3';

[0043] F2 (SEQ ID NO.4):5'-AGCTGAGTACCTGAGAAGAGAGT-3';

[0044] R2 (SEQ ID NO. 5): 5'-CACTGTTCCTTGTCTACTCCCAGA-3'.

[0045] Example 2

[0046] Expression of SRPK3 in the hearts of normal people and patients with myocardial hypertrophy Normal human hearts (individuals donated from non-cardiac deaths) and hearts of patients with myocardial hypertrophy (recipients replaced by patients undergoing heart transplantation or heart biopsy tissues) were selected, and proteins were extracted from the hearts for SDS-PAGE-immunoblotting (Western blot) test. Antibodies specifically recognizing SRPK3 protein and cardiomyocyte hypertrophy markers BNP (Abclonal, A2179) and β-MHC (Abclonal, A7564) were used for detection, and the expression of SRPK3 protein (Invitrogen, PA5-103255) was measured. β-Tubulin (Abmart, M2005L) was used as an internal reference.

[0047] Test results such as Figure 1 As shown, consistent with the up-regulated expression of cardiomyocyte hypertrophy markers BNP and β-MHC, the expression of SRPK3 protein in the hearts of patients with myocardial hypertrophy was significantly up-regulated.

[0048] Example 3

[0049] SRPK3 fl / fl / Myh6-Cre and littermate wild-type SRPK3 fl / fl Male mice were used as experimental subjects, and the mouse myocardial hypertrophy model was established by aortic arch constriction (TAC). The operation process is as follows:

[0050] 1. Preoperative Preparation

[0051] (1) Anesthesia: First weigh the mouse, calculate the amount of anesthetic (3% sodium pentobarbital) required according to 90 mg / kg body weight, inject it intraperitoneally, and record the injection time. The standard for successful anesthesia is that there is no obvious reaction to clamping the tail or toes and the mouse is in good condition (generally, there is no obvious reaction about 10 minutes after injection, and the mouse has a reaction to clamping the toes about 50 minutes after anesthesia. The best time for surgery is about 30 minutes after anesthesia).

[0052] (2) Preparation of surgical area: Remove the hair from the left chest, left chest, and left forelimb of the mouse. After shaving, wipe the surgical area with wet gauze to remove the mouse hair so as not to affect the surgical field of view.

[0053] (3) Tracheal intubation: Use a rubber band to fix the mouse's upper incisors on the slope of the V-shaped board, and quickly insert the tracheal tube into the trachea through the glottis accurately. Then lie on the right side on the heating pad (the heating pad needs to be preheated in advance), and then connect the tracheal tube to the ventilator to fix the mouse. If the mouse's chest rise and fall is consistent with the ventilator frequency, it means that the tracheal intubation is successful.

[0054] 2. TAC surgery

[0055] Model group: The mouse was placed in the right lateral position, with the left forelimb placed above the right forelimb, and the two forelimbs were fixed with medical tape. A cotton swab was placed under the right chest, the chest was raised, and the skin of the surgical area was disinfected with iodine and 75% alcohol by volume. The left chest skin was pinched with ophthalmic forceps in the left hand, and the skin was cut about 1 cm with ophthalmic scissors in the right hand. The muscles and soft tissues were separated in turn, and the chest cavity was opened at the level of the 2nd-3rd ribs. The left lung was slightly opened with a cotton swab, and the descending branch of the aortic arch was freed. The 7-0 surgical suture was passed through the blood vessel, and a 26G (25.0-27.5g mouse) or 27G (23.5-25.0g) syringe needle was placed parallel to the blood vessel. The blood vessel and the needle were ligated together, and then the needle was pulled out to achieve the corresponding degree of vascular constriction. After the ligation was completed, the sutures were sutured in sequence, the chest cavity was closed, and a syringe was inserted into the chest cavity from the suture and 1cc of gas was extracted to restore the negative pressure in the chest cavity. The skin incision was quickly sutured after the syringe was pulled out.

[0056] Sham operation group (Sham): After freeing the descending aorta, only threading was performed without ligation, and the rest of the steps were the same as those in the myocardial hypertrophy model group.

[0057] 3. Postoperative Care

[0058] After TAC surgery, when the mice showed spontaneous breathing and strong toe pinching reactions, the endotracheal tube was removed and the mice were placed in a cage with autoclaved bedding, feed and drinking water and continued to be raised and observed in the breeding room. fl / fl / Myh6-Cre mice and SRPK3 fl / fl The various indicators of the mice were tested 4 weeks after surgery.

[0059] Example 4: Pathological detection of myocardial hypertrophy

[0060] 1. Get materials

[0061] (1) Preliminary work: Prepare a urine cup filled with 20 mL of 10% formaldehyde and label it (mouse number, group, surgery type, and sampling date). Place a petri dish filled with 10% KCl solution at the sampling site. Turn on the analytical balance and adjust it to zero. Weigh and kill the mouse.

[0062] (2) Sampling: Clamp the vascular pedicle below the auricle with ophthalmic curved forceps, cut the heart, and quickly place it in a 10% KCl solution. After the heart stops beating in the diastolic phase, place it on a sterile gauze, gently squeeze the liquid in the heart cavity, wipe the surface liquid dry, weigh and record, place the heart in a corresponding urine cup, and fix it for 48 hours before pathological detection.

[0063] (3) Related measurements and calculations: The heart and lungs of the mice were removed, trimmed, dried with filter paper, weighed and recorded. The skin at the tibia of the hind limbs of the mice was cut open, and the length of the tibia was measured and recorded. The ratio of heart weight to body weight (HW / BW), the ratio of lung weight to body weight (LW / BW) and the ratio of heart weight to tibia length (HW / TL) were calculated.

[0064] (4) Expression of SRPK3 in the hearts of the sham-operated and model-operated mice: The hearts of wild-type C57BL / 6 mice were selected from the sham-operated and model-operated mice at 2 and 4 weeks after TAC surgery, respectively. Proteins were extracted from the hearts and subjected to SDS-PAGE-Western blot. Antibodies that specifically recognize SRPK3 protein and myocardial hypertrophy markers BNP and β-MHC were used to detect the expression of SRPK3 protein. β-Tubulin was used as an internal reference. The results are shown in Table 1. Figure 2 As shown, the expression of cardiomyocyte hypertrophy markers BNP and β-MHC was significantly upregulated 4 weeks after TAC surgery, and the expression of SRPK3 protein was significantly upregulated after TAC surgery.

[0065] 2. Pathological testing

[0066] 2.1 Preparation of paraffin specimen sections

[0067] The main operating procedures include: trimming the heart → embedding frame processing → rinsing with running water → dehydration → transparency → wax dipping → embedding → slicing → spreading slices → drying or baking for later use.

[0068] 2.2 Wheat germ agglutinin (WGA) staining

[0069] Main steps: Place the paraffin specimen sections baked at 60°C for 30 min in xylene for 5 min × 3 times → 100% ethanol for 5 min × 2 times → 95% ethanol for 5 min → 70% ethanol for 5 min → rinse with distilled water for 5 min × 2 times → rinse with PBS for 5 min → rinse with PBS for 10 min → discard PBS, add trypsin working solution (DIG-3008, Fuzhou Maixin) and incubate at 37°C in the dark for 20 min → rinse with PBS for 5 min × 3 times → take out the sections, wipe the liquid around the tissue with filter paper (the tissue must not be dried), draw circles with a histochemical pen and place them flat in a wet box → add WGA-Alexa Flour 488 working solution (10 μg / mL) and incubate at 37°C in the dark for 2 h → discard the staining solution, rinse with PBS for 5 min × 3 times → cover the sections with Slow Fade Gold antifade reagent with DAPI → observe under a fluorescent microscope and take pictures under a microscope.

[0070] 2.3 Masson trichrome staining

[0071] The main steps are: baking at 55℃ for 30min→xylene for 2min, 3 times→100% alcohol for 1min→95% alcohol for 1min→70% alcohol for 1min→washing with running water for 10min→double distilled water for 1min→Weigert's iron hematoxylin staining for 5min→washing with tap water for 5min→removing residual liquid→differentiation with 1% hydrochloric acid alcohol for 4s→washing with tap water for 5min to return to blue→staining with Ponceau acid fuchsin solution for 10min→rinsing with distilled water for 5min→treating with phosphomolybdic acid aqueous solution for about 5min→re-staining with aniline blue solution for 5min→treating with 1% ice CH3COOH for 1min→70% alcohol once→90% alcohol once→100% alcohol for 30s, 3 times→xylene for 2min, 3 times→cover the slide with a glass slide immediately before the xylene dries, and take photos with a microscope. SRPK3 fl / fl / Myh6-Cre and littermates SRPK3 fl / fl The phenotypic results after TAC surgery in mice are shown in Figure 6-8 The heart phenotype of the sham group showed no significant difference, while the heart of the model group was larger than that of the sham group. fl / fl Hearts of SRPK3 / Myh6-Cre mice are significantly smaller fl / fl In addition, SRPK3 in the sham-operated group fl / fl Mice and SRPK3 fl / fl There was no significant difference in HW / BW, LW / BW and HW / TL between / Myh6-Cre mice; SRPK3 fl / fl Four weeks after TAC surgery, the HW / BW, LW / BW, and HW / TL of mice were higher than those of the sham-operated group; fl / fl The HW / BW, LW / BW and HW / TL of SRPK3 / Myh6-Cre mice were significantly higher than those of SRPK3 fl / fl Mice reduced ( Figure 6 ). WGA-stained sections showed: SRPK3 fl / fl / Myh6-Cre group was higher than SRPK3 fl / fl The cell hypertrophy in the group was significantly reduced, and the difference was statistically significant ( Figure 7 ). After Masson staining, it was found that the collagen content of the ventricular myocardial interstitium in the model group was higher than that in the sham operation group, and the increase of collagen around the arterial vessels was more obvious. The collagen thickened and arranged in a disordered network. fl / fl / Myh6-Cre mice after TAC surgery had significantly higher myocardial interstitial collagen content and perivascular collagen content than SRPK3 fl / fl TAC in mice decreased after surgery ( Figure 8 The above results indicate that after TAC surgery, mice developed obvious myocardial hypertrophy and SRPK3 fl / fl / Myh6-Cre mice showed significantly less myocardial hypertrophy and fibrosis than SRPK3fl / fl Mouse.

[0072] Example 5: Echocardiography to detect cardiac function in mice

[0073] 1. Preliminary preparation

[0074] (1) Preparation of the anesthesia machine: First connect the oxygen cylinder to the air inlet interface on the anesthesia machine, then unscrew the sealing cap of the drug inlet on the anesthesia machine, quickly add isoflurane to the safety mark and tighten the sealing cap. Unscrew the main valve on the oxygen cylinder and adjust the knob of the flow control valve to maintain the outlet pressure at 0.2-0.3mPa.

[0075] (2) Preparation of mice to be tested: After the mice to be tested were rapidly anesthetized with isoflurane, the hair on the left chest area was shaved, and the head of the treated mice was inserted into the anesthetic catheter sleeve, and the mice were maintained in a stable anesthesia state with 1.5-2.0% isoflurane.

[0076] 2. Cardiac function test

[0077] The mice were placed in the left lateral decubitus or supine position, and ultrasound coupling agent was evenly applied to the shaved area. A high-frequency ultrasound diagnostic instrument with a frequency of 15 MHz was used to select the standard left ventricular papillary muscle short-axis section to measure the left ventricular end-diastolic diameter, left ventricular end-systolic diameter, left ventricular ejection fraction, and short-axis shortening rate. Fig. 9 It is SRPK3 fl / fl / Myh6-Cre and SRPK3 fl / fl Results of cardiac function test after TAC surgery in mice. fl / fl Compared with mice, SRPK3 fl / fl Four weeks after TAC surgery, mice showed weakened cardiac function and myocardial hypertrophy, mainly manifested by an increase in left ventricular end-diastolic diameter and left ventricular end-systolic diameter, indicators of myocardial hypertrophy, while ejection fraction and fractional shortening, indicators reflecting cardiac function, decreased. fl / fl Cardiac dysfunction in SRPK3 / Myh6-Cre mice fl / fl The mice were relieved.

[0078] Example 6: Expression and Isolation of SRPK3 in Cardiomyocytes after Control Group (PBS) or Angiotensin II (AngII) Stimulation

[0079] Newborn Sprague-Dawley (SD) rat (1-3 days) cardiomyocytes were cultured, and the culture medium was changed after culturing primary cardiomyocytes for 48 hours (the specific process of culturing primary newborn SD rat cardiomyocytes is shown in Example 7 below), serum-free DMEM / F12 was added to starve the cardiomyocytes for 12 hours to synchronize the cells, and then PBS and angiotensin II (AngII, 1 μM) were respectively stimulated for 48 hours, and the protein extracted from the cardiomyocytes was subjected to SDS-PAGE-immunoblotting (Western blot) test, and the expression of SRPK3 protein was determined by combining with an antibody that specifically recognizes SRPK3 protein, and β-Tubulin was used as an internal reference. The test results are as follows: Figure 3 As shown, the expression of SRPK3 was significantly upregulated in cardiomyocytes after angiotensin II (AngII) stimulation.

[0080] Example 7: Effect of SRPK3 interference (Ad-shSRPK3) on AngII-stimulated primary cardiomyocyte hypertrophy

[0081] 1. Primary Culture of Neonatal SD Rat Cardiomyocytes

[0082] (1) Take 10 Sprague-Dawley mice that are 1 to 3 days old, disinfect the area below the neck with 75% alcohol, remove the heart with ophthalmic scissors and microtweezers, and place it in a glass dish containing 10 mL of DMEM / F12. Take another mouse and repeat the above process.

[0083] (2) Wash the heart with DMEM / F12 medium and cut the heart into 1-2 mm 3 Transfer to a serum bottle with a rotor, remove DMEM / F12, add trypsin digestion solution. Rotate at 120r / min, digest for 15min, let stand for a few seconds, and discard the supernatant.

[0084] (3) Add pancreatic enzyme digestion solution, rotate at 120r / min, and digest for 15min. Let it stand for a few seconds, aspirate the supernatant, terminate the digestion with DMEM / F12 medium containing 20% ​​calf serum, and store in a refrigerator at 4℃. Repeat this step several times. Take as much supernatant as possible, and terminate the digestion when the tissue block turns white and becomes obviously smaller.

[0085] (4) Centrifuge the collected cardiomyocyte suspension at 1500 rpm for 8 min and discard the supernatant. Add an appropriate amount of culture medium to the centrifuge tube, gently pipette to resuspend the cells, concentrate into a 50 mL centrifuge tube, and filter the cell suspension with a 40 μm cell filter.

[0086] (5) The cells were seeded in a 100 mm culture dish and allowed to adhere to the wall for 90 minutes. The cell suspension that was not adhered to the wall was aspirated and filtered. BrdU (final concentration 0.1 mM) was added according to the total amount of the cell suspension, mixed well, and then added to a dish coated with 0.1% gelatin.

[0087] (6) Gently shake the cells to disperse them, but do not vortex. Incubate at 37°C, 5% CO2 for 48 hours, wash once with PBS, and replace the culture medium.

[0088] 2. SRPK3 expression interference (Ad-shSRPK3)

[0089] The plasmid pAdeno-CMV-SRPK3-shRNA-EGFP-Puro (see Figure 4 ) and adenovirus backbone vector pADEasy-1 were co-transfected into HEK293 cells to obtain adenovirus Adeno-SRPK3-shRNA-EGFP-Puro, referred to as Ad-shSRPK3, which was amplified and purified to detect the titer and expression level of the target gene SRPK3 (see Figure 4 ) for later use.

[0090] The plasmid pAdeno-CMV-shRNA-EGFP-Puro without the target gene was co-transfected with the adenovirus backbone vector pADEasy-1 into HEK293 cells to obtain the adenovirus Adeno-shRNA-EGFP-Puro, referred to as Ad-shRNA, which was amplified and purified, and the titer was tested for later use.

[0091] Target gene: 5'-GAAAACUGCCUGUUUGUUU-3' (SEQ ID NO. 6);

[0092] shRNA: 5'-UUCUCCGAACGUGUCACGUTT-3' (SEQ ID NO. 7).

[0093] For the cardiomyocyte hypertrophy model induced by AngII, primary cardiomyocytes cultured for 3 days were infected with virus solutions of Ad-shRNA and Ad-shSRPK3 (10MOIs), and then stimulated with 1μM angiotensin II (AngII) (purchased from ENZO, ALX-151-039-M025) or PBS for 48 hours after 12 hours, and then immunofluorescence assay was performed. The results showed that the surface area of ​​cardiomyocytes infected with Ad-shSRPK3 adenovirus was significantly reduced compared with that of the Ad-shRNA control group, that is, the interference of SRPK3 adenovirus inhibited cardiomyocyte hypertrophy ( Figure 5 ).

[0094] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. Use of an inhibitor of SRPK3 gene expression in the preparation of a drug for preventing, alleviating and / or treating myocardial hypertrophy, Features: The sequence of the SRPK3 gene is shown in SEQ ID NO.1, and the SRPK3 gene expression inhibitor is a substance prepared or screened with the SRPK3 gene as the target and has an inhibitory effect on the SRPK3 gene; the SRPK3 gene expression inhibitor includes an interfering plasmid, and the interfering plasmid has a sequence as shown in SEQ ID NO.

6.

2. The use according to claim 1, Features: The interference plasmid is packaged into adenovirus and introduced into cells through adenovirus transfection.

3. The use according to claim 2, Features: The adenovirus is obtained by the following method: co-transfecting the interference plasmid containing the sequence shown in SEQ ID NO.6 and the adenovirus backbone vector pADEasy-1 into HEK 293 cells to obtain the recombinant adenovirus.

4. The use according to claim 1, Features: Myocardial hypertrophy is pathological myocardial hypertrophy, including myocardial hypertrophy caused by one or more of hypertension, aortic stenosis, and mitral valve regurgitation.